SGLT2
39 programs · 38 companies
Programs
39
Companies
38
Active Trials
28
Targeting SGLT2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | Fabry | |
| Tiramavacamten | Roche | Preclinical | SchizophreniaMeso | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | PBCPSP | |
| DSN-7360 | Daiichi Sankyo | Approved | FL | |
| SRP-3270 | Sarepta | Phase 1/2 | LGS | |
| Tirarapivir | United Therapeutics | Approved | Parkinson'sPAH | |
| Pexanaritide | Innovent Bio | Preclinical | Breast CaGIST | |
| Niramavacamten | Hansoh Pharma | Phase 2 | IgANMeso | |
| NTL-2576 | Intellia | NDA/BLA | Pancreatic CaGastric Ca | |
| Liraratamab | Agios | Phase 3 | Cervical CaMelanoma | |
| UCB-8638 | UCB | Phase 1 | GA | |
| Semainavolisib | Jiangsu Hengrui | Phase 2/3 | Urothelial CaPSP | |
| Voxanaritide | Shionogi | Approved | AMLNSCLC | |
| TEM-5063 | Tempus AI | Preclinical | T2DAS | |
| MSK-IIT-499 | MSKCC Breast Svc | Phase 3 | Schizophrenia | |
| MAS-IIT-619 | Mass General Brigham | Phase 2/3 | DLBCL | |
| NCI-IIT-143 | NCI Canada | Phase 2 | RB | |
| NKT-8115 | Nkarta | Phase 2 | GATTR Amyloidosis | |
| Semaglumide | Vanda Pharma | Approved | AngelmanCrohn's | |
| Ribotinib | Kiora Pharma | Phase 1 | Fabry | |
| NUW-823 | Nuwellis (fka CHF Sol) | Phase 1 | Breast CaMigraine | |
| Olpaosocimab | Aimmune | Approved | RSV | |
| ASK-6688 | Asklepios | NDA/BLA | ALLWilms | |
| CHR-2685 | Chroma Med | Phase 2 | Prostate Ca | |
| Semaglumide | Orchard (Kyowa) | Phase 3 | MyelofibrosisEndometrial Ca | |
| Talaglumide | C4 Therapeutics | NDA/BLA | TTR AmyloidosisPBC | |
| Semacagene | Maplewood Bio | Phase 1/2 | NBOCD | |
| TOR-2175 | Torrent Pharma | Preclinical | Crohn'sMM | |
| Lisotinib | Biocon Biologics | Approved | LN | |
| Rimanesiran | Glenmark Pharma | Phase 2/3 | CholangiocarcinomaMyelofibrosis | |
| Surazasiran | Black Diamond | NDA/BLA | AngelmanSchizophrenia | |
| REC-373 | Recordati | Phase 1 | AMLLGS | |
| CAN-IIT-986 | Cancer Hosp CAMS | NDA/BLA | LN | |
| AII-IIT-727 | AIIMS New Delhi | Phase 2/3 | Pompe | |
| FRO-9633 | Frontline BioSciences | Phase 3 | FTDGastric Ca | |
| Doxasacituzumab | Dermavant Sciences | Phase 1 | GBM | |
| SYN-451 | Synlogic | NDA/BLA | ACCMDD | |
| Adagratapinarof | Y Biologics | Phase 3 | GIST | |
| 115-7101 | Bridge Biotherapeutics | Phase 1 | NASHPAH |